Skip Navigation LinksNorthern Ireland Formulary > Formulary > Adult > 3.0 Respiratory System

Formulary - Adult

3.0 Respiratory System

Print page

General advice 

·    Asthma – useful resources:
o   British Guideline on the Management of Asthma’ produced by the British Thoracic Society (BTS) and SIGN 2016
o   NICE NG80 Asthma: diagnosis, monitoring and chronic asthma management, 2017
o   COMPASS therapeutic notes on Management of Asthma
 
·    COPD – useful resources:
o    PrescQIPP ‘Inhaled Therapy in COPD’ bulletin and resources.
 
·     Written personalised action plans as part of self-management education have been shown to improve health outcomes for people with asthma, where appropriate. Personalised asthma action plans are available from PHA and Asthma UK.  Prescribe inhalers only after patients have been trained in their use and demonstrated satisfactory technique. Asthma UK have useful videos and information for patients on ‘using your inhalers’
 
·     Choice of device should be considered on basis of ability to use the inhaler, patient-acceptability and cost. Check medication adherence and inhaler technique before each step up of treatment in asthma. Generally, manually actuated pressurised metered dose inhalers (MDIs) are the cheapest devices available and should usually be first choice provided that the patient can use them efficiently. Consider prescribing a compatible spacer for use with MDI devices in ALL patients, but especially those with sub-optimal inhaler technique prior to switching to a DPI device.
 
·     Changing the type of inhaler device may affect the effectiveness of therapy and the incidence of adverse effects
 
·     It is essential to specify inhaler device, strength and dose. Certain inhaler devices such as those containing beclometasone (+ /- formoterol) and dry powder inhalers are not suitable for generic prescribing
 
·     Not all spacers are compatible with all inhalers; see BNF
 
·     On very rare occasions nebulised bronchodilators may be required when a patient with severe asthma or COPD is unable to use inhalers. Patients should be appropriately assessed before nebulised therapy is deemed appropriate
 
·    If using nebulised salbutamol, 2.5mg unit dose vials (UDVs) should generally be used, which can be repeated if required. Side effects such as tachycardia are more common with the 5mg dose, particularly in elderly patients. In emergency situations, 5mg UDVs may be required. NB –use of nebulised therapy in acute exacerbations of asthma is not covered in this formulary